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Long-term effectiveness and cost-effectiveness
of smoking cessation interventions in patients
with COPD
Martine Hoogendoorn,1 Talitha L Feenstra,2,3 Rudolf T Hoogenveen,2
Maureen P M H Rutten-van Mo¨lken1
ABSTRACT
Background The aim of this study was to estimate the
long-term (cost-) effectiveness of smoking cessation
interventions for patients with chronic obstructive
pulmonary disease (COPD).
Methods A systematic review was performed of
randomised controlled trials on smoking cessation
interventions in patients with COPD reporting 12-month
biochemical validated abstinence rates. The different
interventions were grouped into four categories: usual
care, minimal counselling, intensive counselling and
intensive counselling + pharmacotherapy
(‘pharmacotherapy’). For each category the average
12-month continuous abstinence rate and intervention
costs were estimated. A dynamic population model for
COPD was used to project the long-term (cost-)
effectiveness (25 years) of 1-year implementation of the
interventions for 50% of the patients with COPD who
smoked compared with usual care. Uncertainty and
one-way sensitivity analyses were performed for
variations in the calculation of the abstinence rates, the
type of projection, intervention costs and discount rates.
Results Nine studies were selected. The average
12-month continuous abstinence rates were estimated
to be 1.4% for usual care, 2.6% for minimal counselling,
6.0% for intensive counselling and 12.3% for
pharmacotherapy. Compared with usual care, the costs
per quality-adjusted life year (QALY) gained for minimal
counselling, intensive counselling and pharmacotherapy
were €16 900, €8200 and €2400, respectively. The
results were most sensitive to variations in the
estimation of the abstinence rates and discount rates.
Conclusion Compared with usual care, intensive
counselling and pharmacotherapy resulted in low costs
per QALY gained with ratios comparable to results for
smoking cessation in the general population. Compared
with intensive counselling, pharmacotherapy was cost
saving and dominated the other interventions.
INTRODUCTION
Smoking cessation is still the most important
intervention to slow down the disease progression
of chronic obstructive pulmonary disease
(COPD).1e3 It decreases the annual decline in lung
function,4 reduces symptoms of cough and sputum,
improves health status and reduces exacerbations
of COPD.5 Because of the strong association
between use of healthcare services and disease
severity,6 slowing down disease progression is likely
to reduce annual COPD-related healthcare costs.
Current treatment guidelines recommend that all
patients with COPD who smoke should be offered
the most intensive smoking cessation intervention
feasible.7 8 A review of ﬁve smoking cessation
interventions offered to patients with COPD by
Wagena et al showed that only pharmacotherapy
combined with intensive counselling seemed to be
effective in this patient group. The effects of less
intensive strategies did not reach statistical signiﬁ-
cance.9 A more recent review concluded that coun-
selling plus nicotine replacement therapy (NRT) had
the greatest effect on prolonged abstinence rates in
patients with COPD who smoke.10 Although
almost all smoking cessation interventions targeted
at smokers in the general population are cost-effec-
tive,11 12 little is known about the cost-effectiveness
of smoking cessation interventions offered to
patients who already have a smoking-related disease
like COPD. Since information on the short-term
cost-effectiveness of these interventions in COPD is
already scarce, information on the long-term cost-
effectiveness is virtually absent. It is, however,
highly relevant to know the long-term cost-effec-
tiveness because the health beneﬁts are small in the
ﬁrst year after the intervention but will continue to
increase over time.
The aim of this study was to estimate the impact
of smoking cessation interventions offered to
patients with COPD on the future burden of COPD
using a previously published dynamic population-
based model of COPD disease progression.13
METHODS
Study selection
All randomised controlled trials published in
English investigating the effectiveness of a smoking
cessation intervention in patients with COPD
conﬁrmed by spirometry or physician diagnosis
were included if the follow-up was at least
12 months. The smoking cessation intervention or
therapy had to be the primary intervention and not
part of a disease management or education
programme and abstinence of smoking had to be
biochemically validated.
Search strategy
We performed a literature search in MEDLINE
using the following MeSH headings or words in the
title or abstract: COPD or ‘chronic obstructive
pulmonary disease’ or ‘chronic bronchitis’ in
combination with smoking, tobacco, nicotine or
smok* or nicotin* and one of the following terms:
smoking cessation or tobacco use or quit* or stop*
< Supplementary data are
published online only. To view
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or cessat* or abstin* or abstain*. The search was performed in
February 2009 and was limited to randomised controlled trials
published in English. We also searched the reference lists of
retrieved articles and checked the systematic reviews for further
references. If the search in MEDLINE resulted in studies
reporting 6-month results, but the authors were aware of other
publications in which the 12-month results were presented, the
study was included.
Methodological quality
The methodological quality of the selected studies was evaluated
using the Jadad scale and the Delphi list.14 15 The Jadad scale
consists of ﬁve questions with respect to randomisation and
blinding. Each positive answer to a question was valued with 1
and a negative answer with 0, resulting in a sum score ranging
from 0 to 5.14 The Delphi list consists of nine aspects regarding
randomisation, study population, blinding and presentation of
results. Possible answers were scored as 1 point (‘yes’) or 0 points
(‘no’ or ‘don’t know’), resulting in a sum score ranging from 0 to
9.15 Both scores were assigned independently by two reviewers
(MH and TF/MRvM). Points of disagreement were discussed
until consensus was reached. Both scores were used in combina-
tion to assess the methodological quality of the studies.
Combination of abstinence rates and intervention costs
The interventions performed in the different arms of the
selected trials were grouped into four categories: (1) care as
usualddeﬁned as no counselling or pharmacotherapy or any
other type of smoking intervention offered as part of the trial
(‘usual care’); (2) minimal or brief counselling <90 min in total
(‘minimal counselling’); (3) intensive counselling $90 min
without pharmacotherapy (‘intensive counselling’); and (4)
intensive counselling in combination with any type of phar-
macotherapy (‘pharmacotherapy ’). Interventions offering phar-
macotherapy on a non-compulsory basis were included in the
category with pharmacotherapy if this was used by >50% of the
patients. Patients in the placebo arms of drug trials often
received some form of counselling and were therefore grouped
into the categories ‘minimal counselling’ or ‘intensive counsel-
ling’ depending on the duration of counselling. For our model
calculations we needed absolute quit rates for at least one of the
four intervention categories. We therefore used random effect
meta-analysis16 to account for study heterogeneity and esti-
mated mean abstinence rates for all four categories. The rates
were calculated separately for 12 months continuous abstinence
and 12 months point prevalence abstinence; 12 months contin-
uous abstinence was deﬁned as biochemical validated abstinence
at all measurements up to 12 months including the 12-month
measurement and 12 months point prevalence abstinence was
deﬁned as biochemical validated abstinence at 12 months. We
recalculated the abstinence rates of the intention-to-treat
population assuming subjects with missing data to be smokers
when this was not done in the main analysis of the article.
For studies providing sufﬁcient details about the intervention,
the costs of the intervention were estimated using Dutch unit
costs for the year 2007. Based on these estimates the average
intervention costs for all four intervention categories were
calculated as the weighted means over the studies using the
numbers of patients as weights.
Model
A dynamic population model for COPD was used to estimate
the impact of increased implementation of smoking cessation
interventions compared with usual care.13 The model is
representative for the total Dutch COPD population (306 000
patients in 2000) and is dynamic because changes in the popu-
lation such as birth, mortality, ageing and changing smoking
patterns in the population are taken into account. The model
distinguishes six states: no COPD, four COPD severity stages
(mild, moderate, severe and very severe COPD based on the
GOLD classiﬁcation8) and dead. The prevalence of COPD for the
ﬁrst year of simulation was distributed over the four COPD
severity stages according to the observed severity distribution of
physician-diagnosed patients in the Netherlands.17 For each
following year the model simulates the changes in the number
of patients with COPD, the severity distribution and annual
COPD-related healthcare costs due to incidence, mortality and
disease progression (ie, annual decline in forced expiratory
volume in 1 s (FEV1) percentage predicted). Incidence, mortality
and disease progression are speciﬁed by gender, age, smoking
status and COPD disease severity. COPD-related healthcare
costs are speciﬁed by gender, age and COPD severity. The most
important input parameters of the model are shown in table 1.
An extensive description of the model can be found elsewhere13
and is summarised in the online supplement. The model can be
used for projections of the Dutch COPD population over time
but, more importantly, to evaluate the long-term costs and
health beneﬁts of interventions as was done for this study. The
effects of smoking cessation were modelled as a one-time
increase in FEV1 percentage predicted in the year of smoking
cessation followed by a lower annual decline in FEV1 percentage
predicted based on the Lung Health Study4 and reduced
mortality due to COPD and other smoking-related diseases. The
implementation of smoking cessation interventions for patients
with COPD was modelled by replacing the smoking cessation
rates of usual care by the higher smoking cessation rates of the
intervention for a certain period of time for a certain (part of)
the COPD population. A higher cessation rate compared with
usual care results in more patients with COPD quitting
smoking, slower progression to worse COPD severity stages, less
mortality and a reduction in COPD-related healthcare costs. The
model uses 12-month abstinence rates and accounts for annual
probabilities to relapse in former smokers, so former smokers
may start smoking again >1 year after quitting.13











Prevalence per 1000 people in the general
population*
5.1 10.7 3.0 0.5
Incidence per 1000 people in the general
population*
0.71 0.94 0.08 0.003
Annual decline in FEV1% predictedy
Smokers 1.13 1.50 1.84 2.13
Ex-smokers 0.79 1.17 1.51 1.79
One-time increase in FEV1% predicted
associated with smoking cessation
0.03 2.91 5.56 7.76
Total mortality per 1000 COPD patients in
a specific severity stage*
Smokers 61 73 91 114
Ex-smokersz 51 64 82 104
COPD-related healthcare costs (€, 2007) 318 700 2389 7847
EQ-5D utility weights18 0.8971 0.7551 0.7481 0.5493
*Data from the year 2000, the first year of the simulation.
yData presented as the average for men and women with a mean age of 68 years, the
mean age of the total Dutch COPD population.
zStandardised for the gender, age and COPD severity distribution of the smokers.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s.
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Outcome parameters
The long-term effectiveness of the interventions was expressed
in terms of the cumulative number of life years and quality-
adjusted life years (QALYs) gained and the cumulative reduction
in mortality. QALYs were calculated by weighting life years for
the quality of life during these years in each COPD severity stage
using EQ-5D utility weights (table 1). The cumulative number
of life years, QALYs and deaths over the entire time horizon was
calculated as the sum of the annual number of patients alive, the
annual number of QALYs and the annual number of deaths,
respectively, discounting future outcomes. The cumulative
COPD-related healthcare costs were calculated as the properly
discounted sum of the annual COPD-related healthcare costs
over the time horizon. Finally, the cost per (quality-adjusted) life
year gained was calculated as the ratio of total intervention costs
minus savings in COPD-related healthcare costs compared with
usual care divided by the cumulative (quality-adjusted) life years
gained compared with usual care.
Base case analysis
In the base case analysis we modelled the impact of offering
minimal counselling, intensive counselling or pharmacotherapy
to 50% of the Dutch patients with COPD who smoke (76 000
patients) for 1 year compared with usual care; 50% was chosen
because this percentage of patients with COPD who smoke
reported a willingness to stop smoking within 6 months.19 20
The base case analysis was performed using the mean 12-month
continuous abstinence rates as calculated in the meta-analysis.
Analyses were performed from a healthcare perspective. Effects
and costs were evaluated over a time horizon of 25 years and
were discounted at 1.5% and 4%, respectively, as recommended
by the Dutch guidelines for pharmacoeconomic evaluations.21
Uncertainty and sensitivity analyses
The uncertainty around the outcomes due to the uncertainty
around the calculated abstinence rates and intervention costs
was assessed using the 95% lower and upper limits of the
difference in the abstinence rate compared with usual care and
the minimum and maximum estimates of the intervention
costs. Furthermore, a series of one-way sensitivity analyses was
performed to estimate the impact of the choice of input
parameters on the outcomes. In the ﬁrst sensitivity analysis the
impact of using the 12-month point prevalence rates was
assessed. In the second analysis, effects and costs were not
discounted. For our base case analyses we used absolute quit
rates based on random effect meta-analysis. In the third sensi-
tivity analysis we replaced these by estimating the OR of
minimal counselling, intensive counselling and pharmaco-
therapy versus usual care using a network meta-analysis
approach22 and applied these ORs to the average 12-month
continuous abstinence rate for usual care. In the fourth sensi-
tivity analysis the model was run for the cohort of Dutch
patients with COPD present at the start of the simulations,
assuming no new incidence of COPD. In contrast to the
Netherlands, in many countries nortriptyline is not considered
and/or used for pharmacological smoking cessation support
because it is not registered as such. In the ﬁfth sensitivity
analysis we therefore estimated the outcomes for pharmaco-
therapy excluding the studies on nortriptyline.
RESULTS
The literature search identiﬁed 39 publications of which 26 were
rejected in the ﬁrst selection based on the title and abstract only.
The remaining 13 references were reviewed in full, resulting in
the further exclusion of three papers. One reported abstinence
rates which were not biochemically validated. The other two
studies had a follow-up of 6 months and, to our knowledge, no
other publication was available that reported the results at
12 months. Two publications concerned the same study. This
resulted in the inclusion of 10 papers reporting nine different
studies.2 20 23e30 The characteristics of these studies are shown
in table 2.
The methodological quality of the selected studies is described
in the table in the online supplement. The highest scores were
observed for studies comparing pharmacological treatments
because these studies scored positive on items about ‘double-
blinding’. In studies comparing counselling with, for instance,
usual care, double-blinding is not feasible so they received
a lower quality score. All nine studies were included in the
analyses. The table in the online supplement also shows the
deﬁnitions of abstinence, the method of biochemical validation
and the reported abstinence rates for the interventions in the
different arms of the nine selected studies. Nineteen different
estimates of 12-month continuous abstinence were reported, one
estimate for usual care,20 three for minimal counselling,20 23 24 six
for intensive counselling24e29 31 and nine for pharmacotherapy
(three for NRT, three for bupropion and three for
nortriptyline).23e29 31
The weighted average 12-month continuous abstinence rates
for intensive counselling (6.0%) and for pharmacotherapy
(12.3%) were signiﬁcantly higher than for usual care (1.4%).
This was not the case for minimal counselling with an absti-
nence rate of 2.6% (table 3). Six studies provided sufﬁcient
details to estimate the additional costs of the interventions,
minimal counselling (three estimates20 23 24), intensive coun-
selling (ﬁve estimates24e27) and pharmacotherapy (eight
estimates23e27) compared with usual care. Table 3 shows the
weighted average intervention costs as well as the minimum and
maximum costs observed within the intervention category.
Table 4 shows the results for the base case analysis, 1 year
implementation of the intervention for 50% of the patients with
COPD who smoked and evaluation of outcomes over a 25-year
time horizon. Compared with usual care, the discounted
cumulative number of QALYs gained among this group of
patients with COPD in the Netherlands was 280 for minimal
counselling, 960 for intensive counselling and 2240 for phar-
macotherapy. Figure 1 shows the undiscounted number of
QALYs gained per year over the 25-year time horizon of the base
case analysis. For each of the interventions the maximum gain in
QALYs was observed 10e15 years after implementation.
Compared with usual care, the net costs (difference in inter-
vention costs minus savings in COPD-related healthcare costs)
were €4.83106 for minimal counselling, €7.93106 for intensive
counselling and €6.33106 for pharmacotherapy. Estimates of the
cost-effectiveness compared with usual care ranged from €2400
for pharmacotherapy to €16 900 per QALY gained for minimal
counselling. If each intervention was compared with the next
most effective intervention, the cost per QALY of intensive
versus minimal counselling was €4600, while pharmacotherapy
versus intensive counselling was cost saving.
Uncertainty and sensitivity analyses
Figure 2 shows the uncertainty around the difference in total
costs and the difference in QALYs compared with usual care as
a result of the uncertainty around the 12-month continuous
abstinence rates and the intervention costs. For minimal coun-
selling the results varied from less effective than usual care with
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Table 2 Characteristics of studies included in the review
Study Study population N Severity of COPD
Intervention description (intervention
category*)
Kotz, 200923 Current smokers (>10 pack years) with
previously undetected mild/moderate
airflow limitation recruited from the
general population, aged 35e70 years
who were motivated to quit smoking
296 Mild (FEV1pred >80%) or moderate COPD
(50%<FEV1pred<80%)
Treatment group: Confrontational
counselling (confrontation with spirometry
results) during face-to-face sessions
(160 min) + one telephone session
(5e15 min) by a respiratory nurse plus
nortriptyline for 7 weeks
(pharmacotherapy).
Control group 1: Face-to-face (160 min)
and telephone counselling (5e15 min) by
a respiratory nurse + nortriptyline for
7 weeks (pharmacotherapy).
Control group 2: Care as usual for smoking
cessation provided by the patient’s own
general practitioner (minimal counselling).
Wilson, 200824 Smoking COPD patients treated in an
outpatient respiratory centre with an
intention to stop smoking
91 53% mild (FEV1 >50%), 34% moderate
(30% <FEV1<50%), 13% severe (FEV1
<30%)
All patients: Brief advice to stop smoking
by a physician (5e10 min) + a leaflet
about smoking cessation.
Group 1: Individual support: 5 individual
support sessions (max 60 min) by
a respiratory nurse. Free NRT was offered
but not compulsory (used by 59% of
patients) (pharmacotherapy).
Group 2: Group support: 5 group support
sessions (max 60 min) by a respiratory
nurse. Free NRT was offered but not
compulsory (used by 41% of patients)
(intensive counselling).
Group 3: Control: No further support
(minimal counselling)
Christenhusz, 200725 Patients with clinically treated COPD,
motivated to quit smoking, aged
40e75 years, treated in the outpatient
department of an hospital
225 Moderate (50%<FEV1%pred <69%) and
severe COPD (FEV1%pred <50%)
Group 1: Smoke Stop Therapy (SST)¼
group counselling (360 min), individual
face-to-face (195 min) and telephone
counselling (40 min) by a respiratory
nurse. In case of relapse, individual
sessions ‘recycled’. Pharmacological
support strongly advised. Bupropion
provided free of charge (used by 100% of
patients) (pharmacotherapy).
Group 2: LMIS¼individual (150 min) and
telephone counselling (30 min) by
a respiratory nurse. Pharmacological
support used by choice on own expense
(used by 41% of patients) (intensive
counselling)
Tonnesen, 200626 Smoking patients aged >18 years with
a clinical diagnosis of COPD (FEV1/FVC
<70%, FEV1 <90%) recruited from lung
clinics who were willing to follow the
study protocol
370 9% mild (FEV1 >80%), 53% moderate
(50% <FEV1 <80%), 30% severe (30%
<FEV1 <50%), 8% very severe COPD
(FEV1 <30%)
Low-support: Individual and telephone
sessions (total 150 min) by a respiratory
nurse + take-home material, High support:
individual and telephone sessions (total
270 min) by a respiratory nurse+ take-
home material.
Group 1: low support plus placebo
(intensive counselling)
Group 2: high support plus placebo
(intensive counselling)
Group3: low support + 12 weeks NRT
sublingual tablets (pharmacotherapy)
Group 4: high support + 12 weeks NRT
sublingual tablets (pharmacotherapy)
Wagena, 2005/ Kaper, 200627 28 Current daily smokers with COPD,
smoking for at least 5 years, >10
cigarettes per day, aged 30e70 years,
who were motivated to stop smoking
144 38% mild (FEV1 >80%), 56% moderate
(50% <FEV1 <80%) and 6% severe COPD
(FEV1 <50%)
All patients: individual (total 60 min) and
telephone counselling sessions (total
30 min) by a respiratory nurse.
Group 1: Bupropion for 12 weeks
(pharmacotherapy)
Group 2: Nortriptyline for 12 weeks
(pharmacotherapy)
Group 3: Placebo for 12 weeks (intensive
counselling)
Hilberink, 200520 Smoking COPD patients >35 years
treated by the GP and not under control of
chest physician who were willing to
participate
392 Probably mild/moderate according to
GOLD classification
Group 1: SMOCC: counselling visits to the
GP (1e4 depending on the motivational
stage of change) + maximum of 3
telephone follow-up calls by a respiratory
nurse (mean 50 min per patient) (minimal
counselling).
Group 2: care as usual delivered by the GP
(usual care)
Continued
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higher costs to more effective with cost savings. The results for
intensive counselling ranged from more effective and cost saving
to a maximum possible cost per QALY gained of €44 800, while
for pharmacotherapy the results ranged from more effective and
cost saving to a maximum of €15 700 per QALY gained. The
results of the different sensitivity analyses for all interventions
compared with usual care are shown in table 4. Using the 12-
month point prevalence rates for each of the three types of
interventions and usual care resulted in a slightly lower estimate
of the cost per QALY gained for minimal counselling and
slightly higher estimates for intensive counselling and pharma-
cotherapy versus usual care compared with the base case anal-
ysis. No discounting for both effects and costs also resulted in
lower estimates of the cost per QALY gained, with pharmaco-
therapy even being cost saving. The third sensitivity analysis
resulted in ORs of 2.4, 4.7 and 9.8 for minimal counselling,
intensive counselling and pharmacotherapy, respectively,
compared with usual care. Applying these to the 12-month
continuous abstinence rate of usual care (1.4%) resulted in the
following abstinence rates of 3.3%, 6.4% and 13.2% for minimal
counselling, intensive counselling and pharmcotherapy, respec-
tively. Consequently, the cost-effectiveness of all three inter-
ventions was slightly better than the base case analysis.
Outcomes based on a cohort of patients with COPD instead of
using the dynamic version of the model did not have much
inﬂuence on the results. The ﬁfth sensitivity analysis based on
the 12-month continuous abstinence rate and the weighted
average intervention costs excluding the studies on nortriptyline
(12.0% and €403, respectively) showed an increase in the cost
per QALY for pharmacotherapy compared with usual care from
€2400 to €6100.
DISCUSSION
This study estimated the impact of offering different types of
smoking cessation interventions to patients with COPD. Meta-
analysis showed that both intensive counselling (deﬁned as
>90 min counselling) as well as intensive counselling with any
type of pharmacotherapy were signiﬁcantly more effective than
usual care. The cost-effectiveness ratios for both types of
intervention were low and below €20 000 per QALY gained, the
Table 2 Continued
Study Study population N Severity of COPD
Intervention description (intervention
category*)
Tashkin, 200129 31 Current smokers with stage I or II COPD,
aged >35 years, smoking >15
cigarettes/day for the previous year and
did not quit smoking >3 months in the
previous year who were motivated to quit
smoking
404 Patients with stage I (FEV1%pred >50%)
and stage II (35% <FEV1%pred <50%)
All patients received brief face-to-face
counselling at each of the 9 visits to the
clinic plus 1 telephone session 3 days after
the target quit data.
Group 1: bupropion (pharmacotherapy)
Group 2: placebo (intensive counselling)
Brandt, 199730 Smoking patients with COPD admitted to
the general medical ward of an hospital
56 Probably severe and very severe COPD
according to GOLD
All patients received the same instructions
on how to deal with their disease, the
same encouragement to stop smoking and
the same medical treatment.
Group 1: use of the word ‘smokers’ lung’ in
all information material and by medical
staff (intensive counselling)
Group 2: use of the words ‘chronic
bronchitis’ or ‘emphysema’ (intensive
counselling)
Anthonisen, 19942 Smokers aged 35e60 years with an FEV1/
FVC <70% and 55% <FEV1 <90%
5887 55% <FEV1 <90%, mild and moderate
COPD according to GOLD
Group 1: Physician message, individual
session with interventionist for behavioral
interview, group orientation meeting, 12
intensive group sessions, clinic visits every
4 months for 5 years, maintenance
programme for quitters, extended
intervention programme for patients still
smoking or relapsing and NRT gum plus
ipatropium bromide (Atrovent)
(pharmacotherapy)
Group 2: As for group 1 + placebo inhaler
(pharmacotherapy)
Group 3: Care as usual (usual care)
*The category pharmacotherapy refers to intensive counselling in combination with pharmacotherapy.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LMIS, minimal intervention strategy for lung patients; NRT, nicotine replacement
therapy; SMOCC, smoking cessation in patients with COPD in general practice.
Table 3 Combined abstinence rates for the four interventions groups and associated intervention costs
12-month continuous abstinence rates* 12-month point prevalence rates*
Weightedy average intervention









Usual care 1.4% e 6.8% e 0
Minimal or brief counselling <90 min 2.6% 1.2% (1.3% to 3.7%) 9.0% 2.2% (3.4% to 7.7%) 89 (22e112)
Intensive counselling $90 min 6.0% 4.6% (1.8% to 7.4%) 12.3% 5.5% (1.6% to 12.6%) 205 (93e264)
Intensive counselling $90 min with
pharmacotherapy
12.3% 10.9% (6.9% to 15.0%) 19.0% 12.2% (0.5% to 23.9%) 305 (130e452)
*Based on random effect meta-analysis performed on the absolute abstinence rates in trial arms.
yWeighted by number of patients in the study.
zCalculated based on resource use as described in the individual papers valued using the following unit costs: general practitioner €2.10/min, respiratory physician €5.90/min, respiratory nurse
€0.90/min, information material €1.00, 12 weeks NRT patches €194, 12 weeks NRT tablets €190, 12 weeks NRT gum €178, bupropion €1.30/tablet, nortriptyline €0.16/tablet.
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often used threshold for an intervention to be considered cost-
effective in the Netherlands.32 Comparison of pharmacotherapy
with intensive counselling resulted in cost savings, making
pharmacotherapy the most favourable intervention. The cost
per QALY gained for minimal or brief counselling (deﬁned as
counselling for <90 min) was also below €20 000, but the
effectiveness was not signiﬁcantly different from usual care.
Our literature search on studies reporting the effectiveness
of smoking cessation interventions in patients with COPD
resulted in nine studies. It was therefore impossible to group the
interventions intomore than three or four categories, althoughwe
acknowledge that differences in methods and interventions
within one category existed. Minimal and intensive counselling
are commonly used classiﬁcations in smoking cessation studies
and reviews. The pharmacotherapy category was too small to
subdivide by type, intensity or duration of pharmacotherapy.
Longer duration or greater intensity of pharmacotherapy would
probably lead to higher abstinence rates, although it is not clear
whether this is also true for patients with COPD. With regard to
type of pharmacotherapy, the meta-analysis included three
estimates on each type of pharmacotherapy (bupropion,
nortriptyline and NRT). If, despite the low numbers, the
category pharmacotherapy was subdivided into intensive
counselling plus NRT and intensive counselling plus antide-
pressant, the cost per QALY gained would have been €10 400
for NRT and €600 for antidepressants, both low ratios.
However, more research on the effectiveness of pharmaco-
therapies in patients with COPD is needed to give better
estimates of the cost-effectiveness speciﬁed by type, intensity
of supportive counselling and duration of pharmacotherapy.
Our estimate of pharmacotherapy included the results of
studies offering pharmacotherapy on a non-compulsory basis
if this was used by more than 50% of the patients. This
might have resulted in a potential underestimation of the
effect of pharmacotherapy. Exclusion of the two trials with
non-compulsory pharmacotherapy, however, only had a small
Table 4 Results of the base case and sensitivity analyses (€, 2007): 1-year implementation of minimal counselling, intensive counselling or intensive
counselling in combination with pharmacotherapy (‘pharmacotherapy’) compared with usual care, time horizon 25 years*
Intervention
Type of analysis: base case





















Base case analysis 210 280 90 6.8 2.0 22400 16900
SA1: 12-month point prevalence rates 210 300 160 6.8 2.5 20900 14400
SA2: No discounting 260 340 100 6.8 3.0 14300 11000
SA3: Network meta-analysis 310 420 150 6.8 3.1 11800 8800
SA4: Cohort instead of dynamic 200 260 100 6.8 1.9 24600 18200
Intensive counselling Base case analysis 690 960 340 15.6 7.6 11600 8200
SA1: 12-month point prevalence rates 600 810 280 15.6 5.9 16200 11900
SA2: No discounting 850 1160 380 15.6 11.5 4800 3500
SA3: Network meta-analysis 750 1050 370 15.6 8.3 9600 6900
SA4: Cohort instead of dynamic 680 950 390 15.6 7.4 12000 8600
Pharmacotherapy Base case analysis 1590 2240 830 23.2 17.9 3300 2400
SA1: 12-month point prevalence rates 1260 1740 630 23.2 13.0 8000 5800
SA2: No discounting 1960 2690 910 23.2 26.8 Cost saving Cost saving
SA3: Network meta-analysis 1710 2400 920 23.3 19.2 2300 1600
SA4: Cohort instead of dynamic 1550 2170 850 23.2 17.1 3900 2800
SA5: Excluding studies with nortriptyline 1570 2190 820 30.6 17.3 8500 6100
*Results for pharmcotherapy vs intensive counselling or intensive vs minimal counselling can be calculated as follows: ((intervention costsintervention_B  savings in COPD-related
costintervention_B)  ((intervention costsintervention_A  savings in COPD-related costintervention_A))/(QALYsintervention_B e QALYsintervention_A).
yNumber of deaths avoided over the time horizon of the analyses.
COPD, chronic obstructive pulmonary disease; QALY, quality-adjusted life years.
Figure 1 Annual number of quality-adjusted life years (QALYs) gained
over time for 1-year implementation of minimal or brief counselling,
intensive counselling without pharmacotherapy and intensive counselling
with pharmacotherapy (‘pharmacotherapy’) compared with usual care,
0% discounting.
Figure 2 Uncertainty concerning the difference in total costs and the
difference in quality-adjusted life years (QALYs) for the base case
analysis, 1 year implementation of the intervention compared with usual
care over a time horizon of 25 years, discount rate for effects 1.5% and
for costs 4%. Diamond, minimal or brief counselling; square, intensive
counselling; triangle, intensive counselling plus pharmacotherapy.
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effect on the incremental cost-effectiveness ratio of pharmaco-
therapy (€1900 instead of €2400 per QALY gained).
Our estimates of the 12-month continuous abstinence rates of
intensive counselling (6.0%) and pharmacotherapy (12.3%) were
still relatively low and lower than observed in the general
population (10% and 17%, respectively).33 34 These results
suggest that abstinence rates in patients with COPD are lower
than in ‘healthy ’ smokers. This ﬁnding was also observed in
a study by Wagena et al which showed that patients with COPD
had a 30% higher chance of relapsing than smokers at risk of
COPD.27 By increasing the intensity and duration of counselling
and/or pharmacotherapy, the abstinence rates in COPD may
possibly increase, as shown by the Lung Health Study also
included in our meta-analysis.2 This study is unique in terms of
intensity of the intervention, monitoring of patients and follow-
up, which resulted in remarkably high abstinence rates for the
smoking intervention group but also for the usual care group.
Although the current guidelines advocate the most intensive
smoking cessation intervention, it is questionable whether an
intervention with such a high intensity as the Lung Health
Study is feasible in daily practice.
Results for the cost-effectiveness of pharmacotherapy and
intensive counselling in COPD were comparable with the cost
per QALY gained for smoking cessation support in the general
population. For the general population studies on NRT, bupro-
pion and nortriptyline have shown cost-effectiveness ratios
consistently below €10 000 per (quality adjusted) life year.12 35e38
The cost-effectiveness ratio for minimal counselling in COPD is
somewhat higher than in studies in the general public.11 12 This is
probably a result of the lower abstinence rate and the relatively
high intervention costs compared with other studies on minimal
counselling. In our study, minimal counselling for patients with
COPD consisted of an average of about 25 min counselling while,
in most general population studies, minimal counselling is
deﬁned as <10 min of cessation advice.
The common approach in reviews evaluating the effectiveness
of smoking cessation interventions is to report the RR or OR of
one comparator with the other.9 33 34 The best method to retain
randomisation would be a network meta-analysis. However, in
addition, for a cost-effectiveness analysis the absolute quit rate
for at least one of the interventions or usual care needs to be
estimated. We decided instead to use the averages of the absolute
quit rates as obtained from random effects meta-analysis in our
base case analysis. Estimating ORs and applying them to the
absolute quit rate of usual care would have resulted in a slightly
more favourable cost per QALY estimates for all interventions,
but would not have changed the conclusions much (see third
sensitivity analysis).
In conclusion, compared with usual care, implementation of
intensive counselling with and without pharmacotherapy for
patients with COPD resulted in low costs per QALY gained with
ratios in the range of results presented for smoking cessation
support in the general population. Implementation of minimal
counselling was also cost-effective, but the effectiveness was not
signiﬁcantly different from usual care. Pharmacotherapy in
combination with intensive counselling was cost saving
compared with intensive counselling alone and dominated the
other interventions. These results conﬁrm the advice given in
the guidelines that patients with COPD should be offered the
most intensive smoking cessation intervention feasible, not only
from a clinical but also from an economic perspective.
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Lung alert
CPAP can be considered as an alternative to intubation
and surfactant treatment in extremely preterm infants
In this study of 1316 infants born 24e27 weeks and 6 days gestation, extremely low weight
infants were randomised to receive continuous positive airway pressure (CPAP) treatment in
the delivery room or intubation and surfactant treatment <1 h after birth.
The primary outcome of death was not signiﬁcantly different between treatment groups.
Rates of bronchopulmonary dysplasia (supplemental oxygen requirement at 36 weeks) were
also not signiﬁcantly different. Secondary outcomes in this study showed that infants
receiving CPAP treatment required signiﬁcantly less intubation or postnatal corticosteroids for
bronchopulmonary dysplasia and fewer mechanically ventilated days. Infants treated with
CPAP were also more likely to be alive and off mechanical ventilation by day 7, with no other
signiﬁcantly different adverse outcomes between groups.
This multicentre trial strongly suggests that CPAP in the delivery room can be considered as
an alternative to intubation and surfactant treatment without jeopardising extremely preterm
infant outcome.
< Finer NN, Carlo WA, Walsh MC, et al; SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research
Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010;362:1970e9.
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